Merck Pipeline

Merck Pipeline October 31, 2013

Phase II	Phase II	Phase II	Phase III	Phase III
Allergy, Immunotherapy [1] MK-8237	CMV Prophylaxis in Transplant Patients, letermovir, MK-8228	Migraine MK-1602	Atherosclerosis anacetrapib, MK-0859	HPV-related Cancers, V503 HPV vaccine (9 valent)
Alzheimer's Disease MK-8931 [2]	Contraception, Medicated IUS MK-8342	Overactive Bladder MK-4618	*Clostridium difficile* Infection actoxumab/bezlotoxumab, MK-3415A	➡ Melanoma MK-3475 [5]
➡ Alzheimer's Disease MK-7622	Contraception, Next Generation Ring MK-8175A	Pneumoconjugate Vaccine V114	Contraception NOMAC E2 MK-8175A (US) [3]	Osteoporosis odanacatib, MK-0822
Asthma MK-1029	Contraception, Next Generation Ring MK-8342B	Rheumatoid Arthritis MK-8457	Diabetes Mellitus omarigliptin, MK-3102	Pediatric Hexavalent Combination Vaccine, V419
Bacterial Infection MK-7655	Diabetes ertugliflozin, MK-8835		Hepatitis C vaniprevir, MK-7009 [4]	Platinum-resistant Ovarian Cancer, vintafolide, MK-8109 (US)
Cancer dalotuzumab, MK-0646	Hepatitis C MK-5172		Herpes Zoster Inactivated VZV vaccine, V212	Psoriasis tildrakizumab, MK-3222
Cancer MK-2206	Hepatitis C MK-8742			Thrombosis vorapaxar, MK-5348 (EU)
Cancer ridaforolimus, MK-8669	HIV MK-1439			

1. North American rights.
2. Phase II/III adaptive design.
3. In November 2011, Merck received a CRL from the FDA for NOMAC/E2 (MK-8175A). Merck has made the decision to discontinue the Phase III clinical trial for NOMAC/ E2 being conducted in the United States.
4. For development in Japan only.
5. A new nonproprietary generic name for MK-3475 is under review by United States Adopted Names Council.

Public ➡ Moved forward since last pipeline update.

MERCK Be well

Merck Pipeline as of October 31, 2013

New Molecular Entities	New Molecular Entities	New Indications/Formulations [1]
Under Review	**Approvals [2]**	**Under Review**
Allergy, Grass Pollen [3] MK-7243 (US)	**Atherosclerosis** **LIPTRUZET,** (MK-0653C) (US)	**Antifungal** **NOXAFIL,** MK-5592 (solid oral tablet)
Allergy, Ragweed [3] MK-3641 (US)		**Antifungal** **NOXAFIL,** MK-5592 (IV)
➡ **Fertility** **corifollitropin alfa injection** MK-8962 (US)		
Insomnia **suvorexant** MK-4305 (US) [4]		
Neuromuscular Blockade Reversal **sugammadex** MK-8616 (US) [5]		
Platinum-Resistant Ovarian Cancer **vintafolide** MK-8109 (EU)		
Thrombosis **Vorapaxar** MK-5348 (US)		

1. New indications/formulation updates are solely intended to provide general information regarding Merck projects in development and, for this reason, the information is not represented to be complete.
2. Approvals obtained within the last 12 months.
3. North American rights.
4. In June 2013, Merck received a Complete Response Letter ("CRL") from the FDA for suvorexant (MK-4305). The Company is evaluating the requests in the CRL and plans to submit definitive data in its NDA resubmission to the FDA in the first half of 2014.
5. In September 2013, Merck received a CRL from the FDA for the resubmission of the NDA for sugammadex sodium injection (MK-8616). To address the CRL, the Company intends to conduct a confirmatory hypersensitivity study as soon as practicable, following discussion about the study with FDA.

➡ Moved forward since last pipeline update.

MERCK
Be well

Forward-Looking Statement

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in the presentation set forth below was current as of October 31, 2013. While this presentation remains on the Company's website the Company assumes no duty to update the information to reflect subsequent developments. Consequently, the Company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after October 31, 2013.

The chart reflects the Merck research pipeline as of October 31, 2013.

Candidates shown in Phase III include specific products. Candidates shown in Phase II include the most advanced compound with a specific mechanism in a given therapeutic area. Phase I candidates are not shown.